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Emerging evidence suggests that infection and persistent inflammation are key players 
in the pathogenesis of atherosclerotic cardiovascular disease (CVD). Although it is well 
established that cigarette smoke (CS) promotes atherosclerotic CVD, very little is known 
about the potential impact of the collective effects of CS and intermittent or chronic 
subclinical infection on atherosclerosis. Our previous studies demonstrated that mast 
cell-derived histamine and lipopolysaccharide (LPS) synergistically enhance endothelial 
cell inflammatory response. We further noted that the synergy between histamine and 
LPS was due to reciprocal upregulation of histamine receptor and Toll-like receptor 4 
(TLR4) expression and functions. These results suggest that the combined and per-
sistent effects of mast cell mediators and bacterial agents on the vasculature are risk 
factors of CVD. Our recent data demonstrated that CS extract enhances histamine- and 
LPS-induced expression of cyclooxygenase-2 (COX-2) in endothelial cells, suggesting 
that CS and mast cell mediators may collectively amplify inflammatory response in the 
vessel wall. We hypothesize that CS enhances histamine-mediated upregulation of 
TLR2/TLR4 signaling in the endothelium and promotes progression of atherosclerosis. 
This article presents our perspective on the modulatory effects of CS and nicotine on the 
“histamine-TLR-COX-2 axis.”
Keywords: cigarette smoking, infection, atherosclerosis, mast cells, lipopolysaccharide, histamine, 
cyclooxygenase-2, toll-like receptors 2 and 4
iNtrODUctiON
Atherosclerosis (AS) is the underlying cause of several cardiovascular disease (CVD)-associated 
complications, including myocardial infarction (MI), heart failure, and stroke. Early stages of 
atherogenesis involve endothelial cell activation, persistent inflammatory response, and altered 
vascular homeostasis. The fact that the ever-changing milieu of endothelial cells alters cytokine 
profile, prostanoid homeostasis, and oxidative stress and attracts proinflammatory cells strengthens 
the notion that AS is an inflammatory disease.
November 2015 | Volume 6 | Article 5722
Barua et al. Cigarettes, Innate Immunity and Atherosclerosis
Frontiers in Immunology | www.frontiersin.org
It is recognized that both innate and adaptive immune systems 
contribute to the inflammatory processes in AS. In this respect, 
the role of T-lymphocytes, B-cells, macrophages, dendritic cells, 
natural killer cells, and neutrophils has been extensively studied. 
Furthermore, the presence of increased number of mast cells 
(1–4) and their influence in modulating toll-like receptors (TLRs) 
appear to be key contributors to the atherosclerotic process (5, 
6). The mechanisms by which mast cell-mediated upregulation 
of innate immune system promote progression of AS remain 
obscure.
Toll-like receptors are expressed in a variety of cell types 
including endothelial cells (5). The presence of TLR2 and TLR4 
in endothelial cells and their link to the COX-2 pathway add to 
the interaction between the innate immune system and AS. Our 
laboratory was the first to report the synergy between histamine 
and TLR2/TLR4 signaling that leads to overexpression of COX-2 
and IL-6 in human coronary artery endothelial cells (HCAECs) 
(5–7). We demonstrated that the synergy between histamine and 
bacterial agents is due to reciprocal upregulation of the expres-
sion of histamine H1 receptor (H1R), TLR2, and TLR4. These 
findings strongly suggest that histamine can amplify endothelial 
inflammatory responses initiated by both Gram-positive and 
Gram-negative bacterial products.
Cigarette smoke (CS) is a major lifestyle-related risk factor 
for CVD. However, the impact of CS on intermittent or chronic 
subclinical infection-induced vascular inflammation and athero-
genic pathobiology is unclear. It is well recognized that cigarette 
smoking increases the risk of microbial infection (8), and CS 
induces histamine release from mast cells (9). Thus, it is reason-
able to postulate that cross-communication between CS, hista-
mine, and bacterial products may lead to amplified inflammatory 
response. Here, we present a novel paradigm that CS promotes 
atherogenesis by modulating mast cell-mediated innate immune 
upregulation and by enhancing persistent vascular inflammation.
eNDOtHeLiAL ceLLs AND eArLY 
eveNts iN AtHerOscLerOsis
Endothelial cells constitute the initial site of vascular changes that 
evolve into life-threatening occlusive lesions. The endothelium 
covers the tunica intima of the vessel wall and is directly exposed 
to the circulating milieu and pathogens. Further into the wall, 
the tunica media contains most of the resident smooth muscle 
cells and the adventitia on the outside contains mast cells, nerve 
endings, and microvessels. Endothelial cell activation by blood-
borne proinflammatory agents shifts the vascular tone and local 
vascular homeostasis which, in turn, increase the risk of acceler-
ated development of atherosclerotic lesions (10).
Activation of endothelial cells also increases the expression 
of adhesion molecules (VCAM-1, ICAM-1, and E-selectin) (11) 
that recruit monocytes, T-cells, B-cells, dendritic cells, mast cell 
precursors, and neutrophils into the vascular wall where low-
density lipoprotein (LDL)-laden monocytes mature into foam 
cells. Altered vessel wall environment promotes smooth muscle 
cell proliferation and causes their migration from the media to the 
intima where they synthesize matrix proteins including collagen, 
elastin, and proteoglycans. Immune cells in the developing plaque 
between endothelial cells and the adventitia release proinflamma-
tory cytokines, matrix metalloproteinases (MMPs), and reactive 
oxidants, which ultimately lead to plaque rupture and occlusive 
event (12).
Cardiovascular disease risk factors including cigarette 
smoking, hypercholesterolemia, and oxidative stress cause early 
endothelial dysfunction leading to atherosclerotic changes. 
Endothelial dysfunction is indicated by decreased production of 
vasodilatory and homeostatic molecules such as nitric oxide (NO) 
and prostacyclin (prostaglandin I2, PGI2) or increased production 
of vasoconstrictive molecules such as endothelin-1 (ET-1) and 
thromboxane A2 (TXA2). Early endothelial dysfunction promotes 
the transformation of quiescent endothelial cells toward an active 
phenotype that involves host defense response (13).
rOLe OF cYcLOOXYGeNAse-2 AND 
PrOstANOiDs iN vAscULAr 
iNFLAMMAtiON AND AtHerOscLerOsis
The COX isozymes in concert with specific isomerases modulate 
cellular homeostasis and vascular tone through the production 
of several prostanoids. COX-1 is constitutively expressed in most 
cells, whereas COX-2 expression is induced at sites of inflamma-
tion. COX-2 expression is upregulated in activated macrophages 
and endothelial cells, which makes it a target for the regulation of 
atherogenesis (7, 14). Although COX-2 expression is transient in 
acute inflammation, it can be prolonged or persistent in immune 
disorders (15).
Biological effects of COX products depend on their relative 
concentrations and receptor densities as well as the cell types 
and microenvironment. Among the prostanoids, PGI2 and TXA2 
have received considerable attention because of their opposing 
effects in the vasculature (16). Specific threshold levels of their 
concentrations in systemic circulation and vascular tissues are 
prerequisite for vascular homeostasis (17). PGI2 functions as 
a potent vasodilator and inhibitor of leukocyte adhesion and 
platelet aggregation. Early depletion of PGI2 from endothelium 
promotes AS by enhancing lipid deposition in smooth muscle 
cells (18). In contrast, TXA2 is a potent inducer of vasoconstric-
tion, platelet activation, and platelet adhesion. Therefore, a shift in 
the PGI2/TXA2 equilibrium may dictate the vascular tone.
Our previous work focused on the interaction between hista-
mine and lipopolysaccharide (LPS) with regard to COX-2 expres-
sion in endothelial cells (6, 7). The preferential effect of histamine 
on the induction of COX-2 expression with resultant production 
of PGE2 and PGI2 and its lack of influence on COX-1 expression 
or TXA2 production support the concept of a distinct coupling 
of COX-2 with PGE2 and PGI2 synthases and that of COX-1 with 
TXA2 synthase. It is intriguing that, despite the coexistence of 
both COX-1 and COX-2 in HCAEC, histamine is able to segregate 
its influence on COX-2/PGE2/PGI2 pathway and not on COX-1/
TXA2 pathway. The ability of histamine to synergize LPS-induced 
COX-2 expression and prostanoid production underscores the 
potential role of this mast cell mediator to amplify infection-
associated inflammatory responses. Since a physiological balance 
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in the production of PGI2 and TXA2 by endothelial cells is critical 
for maintaining vascular integrity and controlling thrombosis, 
the histamine-induced shift of prostanoid equilibrium in favor of 
PGI2 production is noteworthy and supports its well-recognized 
vasodilatory and vasoprotective functions.
rOLe OF MAst ceLLs iN vAscULAr 
iNFLAMMAtiON AND AtHerOscLerOsis
Mast cells alter the tissue microenvironment and modulate 
vascular inflammation, progression of AS, cardiac ischemia, 
and CVD (19). Mast cell progenitors reach the tissue through a 
chemokine-mediated mechanism and differentiate into mucosal 
or connective tissue phenotypes. Mucosal mast cells are charac-
terized by the presence of only tryptase and chondroitin sulfate 
(proteoglycan), whereas connective tissue mast cells contain 
tryptase as well as chymase and heparin (proteoglycan) (20). 
Mast cells release vasoactive and angiogenic compounds and 
proinflammatory mediators, such as arachidonic acid metabolites 
(prostaglandin D2, leukotrienes), histamine, cytokines (e.g., IL-6 
and IFNγ) and chemokines (e.g., eotaxin, MCP-1, and RANTES), 
platelet-activating factor (PAF), heparin, and proteolytic enzymes 
(21). These effector molecules are packaged in electron-dense 
secretory granules (mast cell granules, MCG). Endothelial cells 
can endocytose MCG in vitro (22) and in vivo (23). MCG can also 
promote human microvascular endothelial cell proliferation (24), 
LDL uptake by macrophages, and foam cell formation (21, 25).
Risk factors such as hypercholesterolemia, hyperglycemia, 
proinflammatory cytokines, oxidized LDL, reactive oxygen spe-
cies, complement 5a, substance P, endothelin-1, and thrombin can 
activate mast cells (25). Mast cells express proangiogenic cytokine 
βFGF and participate in neovascularization and release histamine 
that increases vascular permeability and proinflammatory effects 
on endothelial cells (26–28). Clinical significance of mast cells 
is evident by their accumulation in the human arterial intima 
and adventitia where they contribute to atherosclerotic plaque 
development as well as its destabilization through their secretory 
products (21, 22, 29). Increased number of mast cells is noted in 
coronary arteries during spasm and in the rupture-prone shoul-
ders of coronary atheromas (2). Although these findings implicate 
mast cells in vascular homeostasis, the mechanism by which they 
promote atherogenesis and CVD is not well understood.
The direct role of mast cells in AS is evident from studies by 
us and others, showing attenuation of AS progression in ApoE−/−/
KitW-sh/W-sh or LDLr−/−/KitW-sh/W-sh mice (30–33). These mouse 
models are generated by crossing AS-prone ApoE−/− or LDLr−/− 
mice with mast cell-deficient KitW-sh/W-sh mice. Using ApoE−/−/ 
KitW-sh/W-sh mice, we demonstrated that mast cell deficiency attenu-
ates AS progression in ApoE−/− mice. Interestingly, the reduction 
in atheroma development in ApoE−/−/KitW-sh/W-sh mice was associ-
ated with marked decreases in hepatic steatosis, reduced serum 
levels of cholesterol, LDL, and HDL, and decreased number of 
T-lymphocytes and macrophages in atheromas. Furthermore, 
ApoE−/−/KitW-sh/W-sh mice presented significantly lower serum IL-6 
and IL-10, with no changes in the levels of IL-2, IL-4, IL-17, IFNγ, 
and TNFα. Mast cell deficiency did not reduce serum levels of 
IFNγ in the ApoE−/− mice, suggesting that mast cell-derived IFNγ 
may not play a role in this mouse model of AS as opposed to the 
LDLr−/− mouse model (31, 34). Mast cell deficiency did not alter 
systemic production of TXA2 in ApoE−/− mice but led to significant 
reduction in the production of PGI2. Significantly lower expres-
sion of COX-2 mRNA in the aortic tissues of ApoE−/−KitW-sh/W-sh 
mice compared with that of ApoE−/− mice suggests that mast cells 
regulate COX-2 expression. In this regard, the ability of histamine 
to induce COX-2 expression and PGI2 production in human 
endothelial cells and the markedly reduced expression of COX-2 
mRNA in the aorta of histidine decarboxylase-null mouse (7) 
emphasize the importance of histamine in prostanoid homeosta-
sis. Taken together, the marked reduction of hypercholesterolemia 
and vascular inflammation due to mast cell deficiency may 
attenuate AS progression in ApoE−/−/KitW-sh/W-sh mice.
rOLe OF HistAMiNe AND H1 recePtOr 
iN eNDOtHeLiAL ceLL iNFLAMMAtOrY 
resPONse
Histamine is a major secretory product of the mast cell that 
regulates vasodilation and bronchoconstriction (33, 35) and acts 
in combination with proteases to destabilize the plaque (35). 
Histamine induces smooth muscle cell migration and prolifera-
tion (36) and regulates intimal thickening (37). Histamine also 
regulates functions of monocytes and macrophages and eosino-
phils (38, 39), T-cells (40), neutrophils, and endothelial cells (41, 
42). Histamine acts through a family of four distinct G-protein-
coupled receptors (GPCR), namely, H1R, H2R, H3R, and H4R 
(43–45). Endothelial cells and smooth muscle cells highly express 
H1R, which facilitates histamine-mediated inflammatory and 
hypersensitivity responses (5–7, 33, 35, 36).
The role of histamine in AS and myocardial damage began to 
emerge only recently (46–48). Coronary arteries of patients with 
ischemic heart disease contain more mast cells and histamine 
than normal vessels (46), and patients with variant angina have 
elevated levels of histamine in their coronary circulation (49). 
Increased H1R mRNA expression has been reported in smooth 
muscle cells of intima/media in the atheroma (50). We found 
that histamine acting through H1R stimulates the expression of 
IL-6 and COX-2, with increased production of PGI2 by human 
endothelial cells. Interestingly, these effects are synergistically 
enhanced by LPS which suggests that mast cell products and 
bacterial agents act in concert to enhance vascular inflammation.
iNFectiON, iNFLAMMAtiON, AND 
AtHerOscLerOsis
Current literature strongly suggests a key role for infection-
related immune activation in AS. Chlamydia pneumoniae, 
Porphyromonas gingivalis, Aggregatibacter actinomycetemcomi-
tans, Helicobacter pylori, and cytomegalovirus have been shown 
to be present in plaques and to promote AS in animals (51–56). 
LPS, a cell wall glycolipid of Gram-negative bacteria, induces the 
production of proinflammatory cytokines and the expression of 
adhesion molecules on endothelial cells. Gram-positive bacterial 
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cell wall components, peptidoglycan (PGN) and lipoteichoic 
acid (LTA), also induce endothelial cell activation (5, 6). LPS is 
detectable in apparently healthy individuals with subclinical or 
chronic infections such as periodontitis, sinusitis, bronchitis, or 
diverticulitis. Persistent LPS levels as low as 50 pg/mL may be a 
strong risk factor for AS, particularly among smokers. Our studies 
demonstrated that bacterial toxins and histamine synergistically 
enhance endothelial inflammatory response through overexpres-
sion of TLR2 and TLR4 (5–7).
Activation of endothelial cells by pathogen-associated molec-
ular patterns (PAMPs) and/or molecules from damaged host 
tissues induce the expression of inflammatory cytokines and cell 
adhesion molecules (57–60). TLRs are innate immune receptors 
that recognize PAMPs (61). TLR4 is the signaling receptor for 
LPS or heat shock protein-60 (human and chlamydial) (62, 63). 
TLR2 recognizes Gram-positive bacterial, mycobacterial, and 
fungal cell wall components (64, 65).
Increasing evidence suggests that TLR2 and TLR4 modulate 
vascular inflammation and atherosclerotic disease (66, 67). 
Endothelial layers of atherosclerotic lesions express higher levels 
of TLR2 and TLR4 mRNA, and patients with loss-of-function 
TLR4 polymorphism have reduced risk of CVD (68). Mutations 
in TLR4 have been linked with a lower incidence of AS and 
other CVDs (69). Furthermore, TLR4 gene deletion reduces 
vascular inflammation and atherogenesis in ApoE−/− mouse 
(70). Anecdotally, it is believed that viral or bacterial infection 
increases the chances for “acute coronary syndrome.” Despite 
putative significance of TLR2 and TLR4 in AS (67–70), an 
association between their expression in the plaque and severity 
of atherosclerotic disease is not established. Our preliminary 
clinical study showed an association between overexpression of 
TLR2, TLR4, and COX-2 in the carotid artery plaque and the 
severity of widespread AS including the presence of peripheral 
artery disease (71). These observations underscore the clinical 
significance of an overactive TLR2/TLR4/COX-2 axis in CVD.
tHe sYNerGY BetWeeN MAst ceLL 
HistAMiNe AND BActeriAL tOXiNs
The TLR-mediated endothelial response to bacterial pathogens 
may be modulated by mast cell mediators. Our studies show 
that histamine acting through H1R stimulates the expression 
of TLR2, TLR4, IL-6, COX-2, PGI2S, and PGE2S genes, leading 
to enhanced production of IL-6, PGE2, and PGI2 by HCAECs 
(5–7). We recently showed that LPS upregulates H1R gene and 
protein expression in HCAECs. We also noted that LPS-exposed 
HCAECs expressed threefold higher H1R than quiescent cells as 
assessed by H1R ligand binding. Furthermore, these cells were 
hyperresponsive to histamine as indicated by increased produc-
tion of PGI2, PGE2, and IL-6. The LPS-induced hyperresponsive-
ness to histamine challenge was found to be mediated via H1R 
since it was abrogated by H1R antagonists (5–7, 72, 73). Thus, 
convergence of reciprocally upregulated H1R and TLR2/TLR4 
functions was evident by the enhanced translocation of NF-κB 
and inflammatory response in endothelial cells treated with 
histamine in the presence of TLR ligands (74).
ciGArette sMOKe, iNNAte iMMUNe 
sYsteM, AND AtHerOscLerOsis
Cigarette smoke is a major cause of cardiovascular morbidity 
and mortality (75, 76). CS predisposes the individual to aortic 
and peripheral AS leading to clinical atherosclerotic syndromes, 
including stable angina, acute coronary syndromes, sudden death, 
and stroke (75). CS impacts all phases of AS from endothelial 
dysfunction to acute clinical events, the latter being largely 
thrombotic (77–84).
TLR recognition is not restricted to exogenous microbial 
patterns. Putative endogenous ligands include fibronectin 
extra domain A fragment, heat shock proteins, and hyaluronan 
fragments. Endogenous ligands may be released during tissue 
damage and drive inflammation in the absence of infection. 
Therefore, a risk factor like CS can potentially promote 
inflammation via these ligands. Indeed, gaseous and particulate 
FiGUre 1 | cigarette smoke extract directly and synergistically with 
histamine or LPs enhances the expression of cOX-2 and tLr4 in 
human endothelial cells. Human umbilical vein endothelial cells (HUVECs) 
were grown to confluence and incubated with (1) medium (control), 
(2) cigarette smoke extract (CSE) (final concentration equivalent to 100 nM 
nicotine), (3) histamine (HIS, 10 μM), (4) HIS + CSE, (5) LPS, 100 ng/mL, 
(6) LPS + CSE, (7) HIS + LPS, and (8) HIS + LPS + CSE for 24 h. After the 
incubation, total RNA was extracted and used for RT-qPCR analyses of gene 
expressions of COX-2 (A) and TLR4 (B). Data presented are mean ± SD of 
quadruplicate experiments. CS increased COX2 gene expression significantly 
compared to control, HIS, LPS, or HIS + LPS groups (P < 0.001). HIS + LPS 
(6) increased COX2 expression compared to control, HIS, or LPS groups 
(P < 0.001). CS increased TLR4 gene expression significantly compared to 
control, HIS, LPS, or HIS + LPS groups (P < 0.001). HIS + LPS (6) increased 
TLR4 expression compared to control, HIS, or LPS groups (P < 0.001).
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constituents of CS increase TLR2, 4, and 6 expression by gingival 
epithelial cells (85). It is worth mentioning that CS may deliver 
bioactive LPS to smokers which may contribute to bronchitis in 
smokers. However, these investigators did not detect differences 
in the circulating levels of LPS between non-smokers and 
smokers (86).
Cigarette smoke upregulates both TLR4 expression and the 
release of IL-8 and LTB4 in alveolar macrophages (87). CS also 
induces TLR4 and MMP4 expression in human small airway 
epithelial (SAE) cells and lung tissue (88). Furthermore, CS 
has been shown to activate mast cells to release preformed 
mediators such as histamine and to inhibit prostaglandin 
production (34).
It is noteworthy that CS not only induces COX-2 expression 
and its enzyme activity but also increases PGE2 and TXA2 release 
(89, 90). CS extract (CSE) and sera from smokers increase COX-2 
expression in endothelial cells (91), and this change is associated 
with augmented angiogenesis in the atherosclerotic plaque. CS 
may exert proinflammatory effects in a PGE2-dependent manner 
while TXA2 may mediate its proatherogenic effect via platelet 
activation, vasoconstriction, and angiogenesis (91).
tHe “H1r–tLr–cOX2 AXis” – AN 
iNteGrAteD APPrOAcH tO stUDY tHe 
iMMUNOMODULAtOrY eFFects OF cs 
AND iNFectiON ON AtHerOGeNesis
We recently conducted a pilot study to test whether CSE directly 
or synergistically modulates the effect of histamine or LPS on 
COX-2 and TLR4 expression in endothelial cells. Briefly, human 
umbilical vein endothelial cells (HUVECs) were incubated with 
medium (control), histamine, or LPS alone and in combina-
tion with CSE for 24 h (see Figure 1). As shown in Figure 1A, 
CSE significantly increased the basal as well as histamine- and 
LPS-induced COX-2 gene expression with varying magnitudes 
of synergy. Similarly, CSE significantly enhanced the expression 
of TLR4 mRNA in quiescent and in histamine- and LPS-treated 
cells (Figure 1B). These results indicate that CS can upregulate 
COX-2 and TLR4 pathways.
We also examined the effect of histamine on the expression 
of nicotinic acetylcholine receptor α1 (NAChRα1) mRNA in 
HUVECs. Histamine upregulated NAChRα1 gene expression, 
which was enhanced by LPS (data not shown). These findings 
suggest that histamine increases endothelial cell sensitivity to 
nicotine and CS through overexpression of NAChRα1. The 
involvement of other nicotinic acetylcholine receptors as well as 
receptors that recognize unidentified factors in CSE remains to 
be determined. Based on these preliminary results, our published 
work (5–7, 72–75, 77–83) and a recent clinical study correlating 
TLR2, TLR4, and COX-2 overexpression in carotid artery plaques 
with the severity of disease (71), we postulate that constituents of 
CS, acting in concert with bacterial toxins and mast cell products, 
may amplify inflammatory response by engaging the H1R-TLR2/
TLR4-COX2 axis (Figure 2).
cONcLUsiON
Mast cells and TLRs are constituents of the innate immune 
system, and they synergistically enhance proatherogenic 
FiGUre 2 | Amplification of endothelial inflammatory response by cigarette smoke (cs) and bacterial products via innate immune upregulation. 
(A) Histamine secreted by the mast cell stimulates H1R on endothelial cells. CS may also increase histamine release. (B) H1R-mediated endothelial cell activation 
leads to increased expression of TLR2/TLR4 and nicotinic acetylcholine receptors (NAChR). This cross talk programs endothelial cells to become hyperresponsive to 
the TLR2/TLR4 ligands (PGN, LTA, and LPS) and CS leading to enhanced inflammatory response. (c) Increased TLR2/TLR4 signaling also increases H1R 
expression. Collective stimulation of newly expressed TLR2/TLR4 and H1R leads to robust proinflammatory changes in the endothelium and persistent vascular 
inflammation.
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